StaphVAX Immunogenicity in Orthopedic Implant Patients

Summary

S. aureus is the most common pathogen involved in prosthetic joint infection. StaphVAX® is a vaccine to prevent these infections, which conjugates the purified capsular polysaccharides of S. aureus to a carrier protein. It is currently being evaluated for future licensing. This study aims to demonstrate the safety and immunogenicity of a single dose of StaphVAX in patients who are candidates for knee or hip arthroplasty.

Timeline

Start

2004-12

Primary completion

2006-06

Completion

2006-10

Drugs

Indications